The potential role for regulatory T-cell therapy in vascularized composite allograft transplantation

Current Opinion in Organ Transplantation

Volumn 19, Issue 6, 2014, Pages 558-565

  Issa, Fadi ^a   Wood, Kathryn J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Immune regulation; Regulatory T cells; Skin transplantation; Vascularized composite allotransplantation

Indexed keywords

ACUTE GRAFT REJECTION; CD4+ T LYMPHOCYTE; GRAFT SURVIVAL; HUMAN; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; PLASTIC SURGERY; REGULATORY T LYMPHOCYTE; REVIEW; SKIN TRANSPLANTATION; VASCULARIZED COMPOSITE ALLOTRANSPLANTATION; ALLOTRANSPLANTATION; ANIMAL; COMPOSITE GRAFT; GRAFT REJECTION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY;

ANIMALS; COMPOSITE TISSUE ALLOGRAFTS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNE TOLERANCE; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84927693581     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000139     Document Type: Review

References (96)

1. Buttemeyer R, Jones NF, Min Z, Rao U. Rejection of the component tissues of limb allografts in rats immunosuppressed with FK-506 and cyclosporine. Plast Reconstr Surg 1996; 97:139-148.
2. Jones ND, Morris PJ, Wood KJ. Differential susceptibility of heart, skin and islet allografts to T cell-mediated rejection. J Immunol 2001; 166:2824-2830.
3. Lee WP, Yaremchuk MJ, Pan YC, et al. Relative antigenicity of components of a vascularised limb allograft. Plast Reconstr Surg 1991; 87:401-411.
4. Barth RN, Nam AJ, Stanwix MG, et al. Prolonged survival of composite facial allografts in nonhuman primates associated with posttransplant lymphopro-liferative disorder. Transplantation 2009; 88:1242-1250.
5. Mundinger GS, Drachenberg CB. Chronic rejection in vascularized composite allografts. Curr Opin Organ Transplant 2014; 19:309-314.
6. Sarhane KA, Tuffaha SH, Broyles JM, et al. A critical analysis of rejection in vascularized composite allotransplantation: clinical, cellular and molecular aspects, current challenges, and novel concepts. Front Immunol 2013; 4:406.
7. Kaufman CL, Ouseph R, Marvin MR, et al. Monitoring and long-term outcomes in vascularized composite allotransplantation. Curr Opin Organ Transplant 2013; 18:652-658.
8. Kaufman CL, Ouseph R, Blair B, et al. Graft vasculopathy in clinical hand transplantation. Am J Transplant 2012; 12:1004-1016.
9. Weissenbacher A, Hautz T, Zelger B, et al. Antibody-mediated rejection in hand transplantation. Transpl Int 2014; 27:e13-e17.
10. Hautz T, Zelger BG, Nasr IW, et al. Lymphoid neogenesis in skin of human hand, nonhuman primate, and rat vascularized composite allografts. Transpl Int 2014; 27:966-976.
11. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133:775-787.
12. Brunkow ME, Jeffery EW, Hjerrild KA, et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001; 27:68-73.
13. Ochs HD, Ziegler SF, Torgerson TR. FOXP3 acts as a rheostat of the immune response. Immunol Rev 2005; 203:156-164.
14. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007; 8:191-197.
15. Lahl K, Loddenkemper C, Drouin C, et al. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J Exp Med 2007; 204:57-63.
16. +Foxp3+ T cell accumulation during a human cutaneous antigen-specific memory response in vivo. J Clin Invest 2008; 118:3639-3650.
17. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353:2342-2351.
18. Yang H, Ding R, Sharma VK, et al. Hyperexpression of Foxp3 and IDO during acute rejection of islet allografts. Transplantation 2007; 83:1643-1647.
19. Bunnag S, Allanach K, Jhangri GS, et al. FOXP3 expression in human kidney transplant biopsies is associated with rejection and time post transplant but not with favorable outcomes. Am J Transplant 2008; 8:1423-1433.
20. Dijke IE, Velthuis JH, Caliskan K, et al. Intragraft FOXP3 mRNA expression reflects antidonor immune reactivity in cardiac allograft patients. Transplantation 2007; 83:1477-1484.
21. Hautz T, Brandacher G, Zelger B, et al. Indoleamine 2,3-dioxygenase and foxp3 expression in skin rejection of human hand allografts. Transplant Proc 2009; 41:509-512.
22. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-1061.
23. Karim M, Kingsley CI, Bushell AR, et al. Alloantigen-induced CD25+CD4+ regulatory T cells can develop in vivo from CD25-CD4+ precursors in a thymus-independent process. J Immunol 2004; 172:923-928.
24. Kingsley CI, Karim M, Bushell AR, Wood KJ. CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002; 168:1080-1086.
25. Karim M, Feng G, Wood KJ, Bushell AR. CD25+CD4+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen-specific reactivation in vivo is critical for bystander regulation. Blood 2005; 105:4871-4877.
26. Toker A, Engelbert D, Garg G, et al. Active demethylation of the Foxp3 locus leads to the generation of stable regulatory T cells within the thymus. J Immunol 2013; 190:3180-3188.
27. Polansky JK, Kretschmer K, Freyer J, et al. DNA methylation controls Foxp3 gene expression. Eur J Immunol 2008; 38:1654-1663.
28. McMurchy AN, Bushell A, Levings MK, Wood KJ. Moving to tolerance: clinical application of T regulatory cells. Semin Immunol 2011; 23:304-313.
29. Mottet C, Uhlig HH, Powrie F. Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells. J Immunol 2003; 170:3939-3943.
30. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155:1151-1164.
31. Kingsley CI, Nadig SN, Wood KJ. Transplantation tolerance: lessons from experimental rodent models. Transpl Int 2007; 20:828-841.
32. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4:330-336.
33. Ephrem A, Epstein AL, Stephens GL, et al. Modulation of Treg cells/T effector function by GITR signaling is context-dependent. Eur J Immunol 2013; 43:2421-2429.
34. Chen ML, Yan BS, Bando Y, et al. Latency-associated peptide identifies a novel CD4+CD25+ regulatoryT cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis. J Immunol 2008; 180:7327-7337.
35. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322:271-275.
36. Marson A, Kretschmer K, Frampton GM, et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007; 445:931-935.
37. Issa F, Wood KJ. CD4+ regulatory T cells in solid organ transplantation. Curr Opin Organ Transplant 2010; 15:757-764.
38. Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 2007; 445:766-770.
39. Francis RS, Feng G, Tha-In T, et al. Induction of transplantation tolerance converts potential effector T cells into graft-protective regulatory T cells. Eur J Immunol 2011; 41:726-738.
40. Feng G, Nadig SN, Backdahl L, et al. Functional regulatory T cells produced by inhibiting cyclic nucleotide phosphodiesterase type 3 prevent allograft rejection. Sci Transl Med 2011; 3:83ra40.
41. Feng G, Wood KJ, Bushell A. Regulatory T cell enrichment by IFN-gamma conditioning. Methods Mol Biol 2011; 677:281-301.
42. Apostolou I, Verginis P, Kretschmer K, et al. Peripherally induced Treg: mode, stability, and role in specific tolerance. J Clin Immunol 2008; 28:619-624.
43. Gavin MA, Torgerson TR, Houston E, et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A 2006; 103:6659-6664.
44. Williams LM, Rudensky AY. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol 2007; 8:277-284.
45. Issa F, Wood KJ. Translating tolerogenic therapies to the clinic: where do we stand? Front Immunol 2012; 3:254.
46. Battaglia M, Stabilini A, Migliavacca B, et al. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177:8338-8347.
47. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105:4743-4748.
48. Milward K, Issa F, Hester J, et al. Multiple unit pooled umbilical cord blood is a viable source of therapeutic regulatory T cells. Transplantation 2013; 95:85-93.
49. Landwehr-Kenzel S, Issa F, Luu SH, et al. Novel GMP-compatible protocol employing an allogeneic B cell bank for clonal expansion of allospecific natural regulatory T cells. Am J Transplant 2014; 14:594-606.
50. Putnam AL, Safinia N, Medvec A, et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am J Transplant 2013; 13:3010-3020.
51. Wood KJ, Bushell A, Hester J. Regulatory immune cells in transplantation. Nat Rev Immunol 2012; 12:417-430.
52. Mathes DW, Randolph MA, Solari MG, et al. Split tolerance to a composite tissue allograft in a swine model. Transplantation 2003; 75:25-31.
53. Cetrulo CL Jr, Torabi R, Scalea JR, et al. Vascularized composite allograft transplant survival in miniature swine: is MHC tolerance sufficient for acceptance of epidermis? Transplantation 2013; 96:966-974.
54. Issa F, Hester J, Goto R, et al. Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model. Transplantation 2010; 90:1321-1327.
55. Sagoo P, Ali N, Garg G, et al. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med 2011; 3:83ra42.
56. Issa F, Hester J, Milward K, Wood KJ. Homing of regulatory T cells to human skin is important for the prevention of alloimmune-mediated pathology in an in vivo cellular therapy model. PLoS One 2012; 7:e53331.
57. Clark RA, Chong B, Mirchandani N, et al. The vast majority of CLA+ Tcells are resident in normal skin. J Immunol 2006; 176:4431-4439.
58. Sather BD, Treuting P, Perdue N, et al. Altering the distribution of Foxp3(+) regulatory T cells results in tissue-specific inflammatory disease. J Exp Med 2007; 204:1335-1347.
59. Lee I, Wang L, Wells AD, et al. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med 2005; 201:1037-1044.
60. Kanitakis J, Jullien D, Petruzzo P, et al. Clinicopathologic features of graft rejection of the first human hand allograft. Transplantation 2003; 76:688-693.
61. Humar A, Hassoun A, Kandaswamy R, et al. Immunologic factors: the major risk for decreased long-term renal allograft survival. Transplantation 1999; 68:1842-1846.
62. Issa F, Chandrasekharan D, Wood KJ. Regulatory T cells as modulators of chronic allograft dysfunction. Curr Opin Immunol 2011; 23:648-654.
63. Nadig SN, Wieckiewicz J, Wu DC, et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010; 16:809-813.
64. Warnecke G, Feng G, Goto R, et al. CD4+ regulatory T cells generated in vitro with IFN-{gamma} and allogeneic APC inhibit transplant arteriosclerosis. Am J Pathol 2010; 177:464-472.
65. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012; 30:531-564.
66. Horner BM, Ferguson KK, Randolph MA, et al. In vivo observations of cell trafficking in allotransplanted vascularized skin flaps and conventional skin grafts. J Plast Reconstr Aesthet Surg 2010; 63:711-719.
67. Nasir S, Bozkurt M, Krokowicz L, et al. Correlation of chimerism with graft size and revascularization in vascularized and nonvascularized skin allografts. Ann Plast Surg 2009; 62:430-438.
68. Walch JM, Zeng Q, Li Q, et al. Cognate antigen directs CD8+ T cell migration to vascularized transplants. J Clin Invest 2013; 123:2663-2671.
69. Perloff LJ, Barker CF. The immediately vascularized skin allograft. Transplantation 1979; 28:125-130.
70. Lin CH, Zhang W, Ng TW, et al. Vascularized osteomyocutaneous allografts are permissive to tolerance by induction-based immunomodulatory therapy. Am J Transplant 2013; 13:2161-2168.
71. Horibe EK, Sacks J, Unadkat J, et al. Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion. Transpl Immunol 2008; 18:307-318.
72. Kuo YR, Goto S, Shih HS, et al. Mesenchymal stem cells prolong composite tissue allotransplant survival in a swine model. Transplantation 2009; 87:1769-1777.
73. Bigenzahn S, Blaha P, Koporc Z, et al. The role of nondeletional tolerance mechanisms in a murine model of mixed chimerism with costimulation blockade. Am J Transplant 2005; 5:1237-1247.
74. World Transplant Congress 2014, San Francisco, USA. Poster Sessions: Basic. Am J Transplant 2014; 14:278-419.
75. Xu H, Ramsey DM, Wu S, et al. Simultaneous bone marrow and composite tissue transplantation in rats treated with nonmyeloablative conditioning promotes tolerance. Transplantation 2013; 95:301-308.
76. Leonard DA, Kurtz JM, Mallard C, et al. Vascularized composite allograft tolerance across MHC barriers in a large animal model. AmJ Transplant 2014; 14:343-355.
77. Mathes DW, Chang J, Hwang B, et al. Simultaneous transplantation of hematopoietic stem cells and a vascularized composite allograft leads to tolerance. Transplantation 2014; 98:131-138.
78. Bozulic LD, Wen Y, Xu H, Ildstad ST. Evidence that FoxP3+ regulatory T cells may play a role in promoting long-term acceptance of composite tissue allotransplants. Transplantation 2011; 91:908-915.
79. Qin SX, Wise M, Cobbold SP, et al. Induction of tolerance in peripheral T cells with monoclonal antibodies. Eur J Immunol 1990; 20:2737-2745.
80. Wekerle T, Kurtz J, Ito H, et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000; 6:464-469.
81. Wekerle T, Sayegh MH, Ito H, et al. Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a nonmyeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance. Transplantation 1999; 68:1348-1355.
82. Durham MM, Bingaman AW, Adams AB, et al. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000; 165:1-4.
83. Seung E, Mordes JP, Rossini AA, Greiner DL. Hematopoietic chimerism and central tolerance created by peripheral-tolerance induction without myeloa-blative conditioning. J Clin Invest 2003; 112:795-808.
84. Lin JY, Tsai FC, Wallace CG, et al. Combined treatment with regulatory T cells and vascularized bone marrow transplantation creates mixed chimerism and induces donor-specific tolerance to vascularized composite allografts without cytoreductive conditioning. Chimerism 2013; 4:20-22.
85. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant 2006; 6:1774-1780.
86. Orlando G, Hematti P, Stratta RJ, et al. Clinical operational tolerance after renal transplantation: current status and future challenges. Ann Surg 2010; 252:915-928.
87. Koshiba T, Li Y, Takemura M, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol 2007; 17:94-97.
88. Li Y, Koshiba T, Yoshizawa A, et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004; 4:2118-2125.
89. Li Y, Zhao X, Cheng D, et al. The presence of Foxp3 expressing T cells within grafts of tolerance human liver transplant recipients. Transplantation 2008; 86:1837-1843.
90. Martinez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7:309-319.
91. Sagoo P, Perucha E, Sawitzki B, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest 2010; 120:1848-1861.
92. Moraes-Vieira PM, Silva HM, Takenaka MC, et al. Differential monocyte STAT6 activation and CD4(+)CD25(+)Foxp3(+) T cells in kidney operational tolerance transplanted individuals. Hum Immunol 2010; 71:442-450.
93. Eljaafari A, Badet L, Kanitakis J, et al. Isolation of regulatory T cells in the skin of a human hand-allograft, up to six years posttransplantation. Transplantation 2006; 82:1764-1768.
94. Brazio PS, Munivenkatappa RB, Bojovic B, et al. Regulatory T cells are not predictive of outcomes in a nonhuman primate model of vascu-larized composite allotransplantation. Transplantation 2013; 96:267-273.
95. Hester J, Schiopu A, Nadig SN, Wood KJ. Low-dose rapamycin treatment increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo. Am J Transplant 2012; 12:2008-2016.
96. Safinia N, Vaikunthanathan T, Fraser H, et al. A GMP Treg expansion protocol restores Treg suppressor function in end-stage liver disease: implications for adoptive transfer therapy. Gut 2014; 63:A92-A93.